This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Tenet Healthcare (THC) in Focus: Stock Moves 8.5% Higher
by Zacks Equity Research
Tenet Healthcare (THC) shares rose nearly 9% in the last trading session, amid huge volumes.
Alexion (ALXN) in Focus: Stock Moves 7.2% Higher
by Zacks Equity Research
Alexion (ALXN) shares rose more than 7% in the last trading session, amid huge volumes.
Why AveXis (AVXS) Could Be Positioned for a Slump
by Zacks Equity Research
AveXis (AVXS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) shares rose nearly 18% in the last trading session, amid huge volumes.
Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day
Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why
by Madeleine Johnson
On Thursday, shares of biopharmaceutical company Akari Therapeutics (AKTX) are skyrocketing, up over 60% in midday trading--the stock was up 90% in premarket trading--after it announced it would advance its lead drug candidate.
Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%
by Zacks Equity Research
Idera Pharmaceuticals (IDRA) shares rose more than 14% in the last trading session, amid huge volumes.
NewLink Genetics (NLNK) Jumps: Stock Rises 29.9%
by Zacks Equity Research
NewLink Genetics (NLNK) shares rose nearly 30% in the last trading session, amid huge volumes.
Athersys (ATHX) in Focus: Stock Moves 10.22% Higher
by Zacks Equity Research
Athersys (ATHX) was a big mover last session, as the company saw its shares rise more than 10% on the day.
Regenxbio (RGNX) in Focus: Stock Moves 9.5% Higher
by Zacks Equity Research
Regenxbio (RGNX) was a big mover last session, as the company saw its shares rise more than 9% on the day.
BioMarin (BMRN) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
BioMarin (BMRN) shares rose nearly 6% in the last trading session, amid huge volumes.
Cellectis (CLLS) Catches Eye: Stock Jumps 17%
by Zacks Equity Research
Cellectis (CLLS) shares rose 17% in the last trading session, amid huge volumes.
Amgen Evenity Approval Derailed on Cardiovascular Side Effect
by Zacks Equity Research
A late-stage study at Amgen, Inc. (AMGN) showed that its pipeline candidate Evenity/romosozumab led to a statistically significant superior fracture risk reduction.
What Falling Estimates & Price Mean for AveXis, Inc. (AVXS)
by Zacks Equity Research
It seems wise to sell the AveXis, Inc. (AVXS) stock at this moment as its both estimates and price have been witnessing downward revision.
BioDelivery Sciences International (BDSI) Jumps: Stock Up 5%
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) shares rose over 5% in the last trading session.
Why Is Vertex Pharma (VRTX) Stock Soaring This Year?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc.'s (VRTX) shares have risen 57.8% this year so far, outperforming the increase of 1.3% for the Zacks classified Large-Cap Pharma industry.
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M
by Zacks Equity Research
Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).
Geron Corp (GERN) Worth a Look: Stock Adds 7% in Session
by Zacks Equity Research
Geron Corporation (GERN) shares rose over 7% in the last trading session.
Bear of the Day: AMAG Pharmaceuticals (AMAG)
by Brian Hamilton
Licensing expenses, increased SG&A, and limited market share expansion are weighing this stock down.
Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.
Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate
Geron (GERN) Q1 Loss In Line, Focus Remains on Imetelstat
by Zacks Equity Research
Geron Corporation (GERN) reported a loss of 5 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate. In the year-ago quarter.
Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) reported first-quarter 2017 loss of $1.33 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.43 as well as the year-ago loss of $2.17 per share.
Akari Therapeutics (AKTX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Akari Therapeutics PLC (AKTX).
Will Akari Therapeutics (AKTX) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Akari Therapeutics PLC (AKTX).